Reevaluation of Systematic Evaluation of the Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma
10.11969/j.issn.1673-548X.2023.11.028
- VernacularTitle:TACE联合索拉非尼治疗不可切除肝细胞癌疗效及安全性系统评价再评价
- Author:
Zhaojun LIANG
1
,
2
;
Baoyin ZHAO
;
Lixia ZHANG
Author Information
1. 730050 兰州,中国人民解放军联勤保障部队第九四〇医院消化内科
2. 750004 银川,宁夏医科大学临床医学院
- Keywords:
Transcatheter arterial chemoembolization;
Sorafenib;
Hepatocellular carcinoma;
Reevaluation of systematic evaluation
- From:
Journal of Medical Research
2023;52(11):142-148
- CountryChina
- Language:Chinese
-
Abstract:
Objective To conduct reevaluation of systematic review/Meta-analysis on the efficacy and safety of transcatheter arteri-al chemoembolization(TACE)combined with sorafenib in the treatment of unresectable hepatocellular carcinoma(HCC).Methods The systematic reviews and Meta-analysis of TACE combined with sorafenib in the treatment of HCC were collected through computer searches on PubMed,Embase,the CochraneLibrary,CNKI and Wanfang data knowledge service platform.The time limit was from data-base inception to August 2022.The experimental group received TACE combined with sorafenib,and the control group received other con-ventional treatments.After screening the literature and extracting the data,PRISMA statement was adopted to evaluate the quality of the included reports,AMSTAR 2scale was used for methodological quality evaluation,and GRADE tool was used for outcome indicator and evidence quality evaluation.Results A total of 9 literatures were included,including 43 outcome indicators.The PRISMA score was 20.5-25.5,including 7 articles of high quality and 2 articles of moderate quality.The results of AMSTAR 2 quality evaluation show that all the literatures were of extremely low quality,and the key items with the most problems were item 2 and item 7.The results of GRADE evaluation showed that there were 4 high quality indicators,15medium quality indicators,21 low quality indicators and 3 unevaluable indi-cators.The main factor leading to degradation was bias risk,followed by inconsistency.In terms of curative effect,compared with the con-trol group,the 1-year survival rate,time to progression,objective response rate and disease control rate of patients in the experimental group were significantly improved.However,the incidence of adverse reactions(diarrhea,hand and foot syndrome,hypertension)in the control group was significantly better than those in the experimental group.Conclusion The methodology quality and evidence quality of systematic review/Meta-analysis related to TACE combined with sorafenib in the treatment of HCC is poor,and the standardization still needs to be further improved.
